NOVANTA INC 8-K
PositiveEarningsNew guidance
Riverpoint Medical acquisition roughly doubles recurring medical consumables to ≈25% of annualized sales; immediate margin and EPS gains expected.
Filed 2026-08-05 16:50 ET
- 2.02 Results of Operations
- 9.01 Financial Statements and Exhibits
Summary
Q2 2026 results with Q3 and FY2026 guidance. Revenue grew 10.3% Y/Y, including 9.3% organic growth, Novanta’s strongest organic growth quarter since Q1 2023. The company said its recently closed Riverpoint Medical acquisition is expected to immediately contribute to revenue growth, gross margins, EBITDA margins and EPS; it roughly doubles recurring medical consumables to ≈25% of annualized sales and brings medical end-market exposure to ≈60%. The company will discuss results and provide a business update on its 8/6/2026 conference call.
Key Figures
| Metric | Q2 2026 | YTD 2026 |
|---|---|---|
| Revenue | $265.8M, +10.3% Y/Y | — |
| Gross margin (GAAP) | 45.5%, vs 44.3% | — |
| Gross margin (non-GAAP, adjusted) | 47.1%, vs 46.1% | — |
| Operating income (GAAP) | $18.1M, +21.1% Y/Y | — |
| Net income (GAAP) | $12.5M, vs $4.5M | — |
| Diluted EPS (GAAP) | $0.30, vs $0.12 | — |
| Diluted EPS (non-GAAP, adjusted) | $0.89, +17.1% Y/Y | — |
| Adjusted EBITDA (non-GAAP) | $60.7M, +16.4% Y/Y | — |
| Operating cash flow | $64.9M, vs $15.1M | $116.5M, +149% Y/Y |
| Free cash flow (non-GAAP) | $57.5M, vs $11.7M | — |
- Revenue growth included a $2.4M, or 1.0 percentage-point, benefit from foreign currency; organic revenue growth was 9.3%.
- Cash was $718.7M at 7/3/2026, vs $380.9M at 12/31/2025. Total debt was $229.7M and net debt was $(479.9)M; the quarter included $288.5M of net proceeds from a private share placement.
Guidance
| Metric | Period | Guidance | Prior | Direction |
|---|---|---|---|---|
| Revenue (GAAP) | Q3 2026 | $300M-$304M; >21% growth | — | — |
| Adjusted EBITDA (non-GAAP) | Q3 2026 | $74M-$77M | — | — |
| Adjusted diluted EPS (non-GAAP) | Q3 2026 | $0.95-$1.00 | — | — |
| Revenue (GAAP) | FY2026 | $1.13B-$1.14B; >15% growth | — | — |
| Adjusted EBITDA (non-GAAP) | FY2026 | $273M-$278M; >24% growth | — | — |
| Adjusted diluted EPS (non-GAAP) | FY2026 | $3.68-$3.74; >12% growth | — | — |
Guidance incorporates the expected Riverpoint contribution and assumes no significant foreign-exchange changes.
Investor Takeaways
- Watch Q3 revenue, adjusted EBITDA and adjusted diluted EPS against the guided ranges.
- Track whether Riverpoint delivers the expected immediate contribution to growth and margins.
The summary is written by an AI model reading the filing.
Model 005 · prompt 5998ea898f · 2026-10-16 20:30:44Z